Cullinan Therapeutics (CGEM) Free Cash Flow (2020 - 2026)
Cullinan Therapeutics (CGEM) posted quarterly Free Cash Flow of -$46.0 million for Q1 2026, down 6.7% year-over-year from -$49.3 million in Q1 2025, and down 20.79% quarter-over-quarter from -$38.1 million in Q4 2025.
Powered by 
Analysis
Cullinan Therapeutics (CGEM) Free Cash Flow (2020 - 2026) Analysis & Trends
Cullinan Therapeutics' Free Cash Flow history runs 7 years deep, the most recent figure standing at -$46.0 million for Q1 2026.
- In Q1 2026, Free Cash Flow fell 6.7% year-over-year to -$46.0 million; the TTM figure through Mar 2026 stood at -$178.7 million (down 18.93% YoY), while the FY2025 annual figure was -$175.8 million, down 20.99% from the prior year.
- Free Cash Flow for Q1 2026 stood at -$46.0 million, down from -$38.1 million in the prior quarter.
- The five-year high for Free Cash Flow was -$18.1 million in Q4 2023, with the low at -$57.6 million in Q2 2025.
- The 5-year median for Free Cash Flow is -$36.6 million (2024), against an average of -$37.0 million.
- The sharpest annual moves came in 2022 and 2023: Free Cash Flow tumbled 1346.07% in 2022, then soared 37.48% in 2023.
- Cullinan Therapeutics' Free Cash Flow stood at -$25.9 million in 2022, then increased by 29.9% to -$18.1 million in 2023, then plunged by 102.01% to -$36.6 million in 2024, then dropped by 4.08% to -$38.1 million in 2025, then fell by 20.79% to -$46.0 million in 2026.
- Business Quant data shows CGEM's Free Cash Flow at -$46.0 million in Q1 2026, -$38.1 million in Q4 2025, and -$36.9 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -563.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -389.61 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 437.80 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 292.04 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 477.44 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -95.09 Mn |
| 10 | Cullinan Therapeutics | 1.37 Bn | 1.37 Bn | - | -38.22 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -38.22 Mn |
| Mar 31, 2026 | -46.05 Mn |
| Dec 31, 2025 | -38.12 Mn |
| Sep 30, 2025 | -36.88 Mn |
| Jun 30, 2025 | -57.61 Mn |
| Mar 31, 2025 | -43.16 Mn |
| Dec 31, 2024 | -36.63 Mn |
| Sep 30, 2024 | -34.14 Mn |
| Jun 30, 2024 | -36.29 Mn |
| Mar 31, 2024 | -38.25 Mn |
| Dec 31, 2023 | -18.13 Mn |
| Sep 30, 2023 | -34.14 Mn |
| Jun 30, 2023 | -31.06 Mn |
| Mar 31, 2023 | -51.16 Mn |
| Dec 31, 2022 | -25.87 Mn |
| Sep 30, 2022 | -54.60 Mn |
| Jun 30, 2022 | -25.42 Mn |
| Mar 31, 2022 | -21.91 Mn |
| Dec 31, 2021 | -15.17 Mn |
| Sep 30, 2021 | -10.55 Mn |